Q BioMed Inc., a biotechnology acceleration company, has signed a collaborative agreement with SRI International to provide formulation development, preclinical development, and early clinical manufacturing of QBM-001, in support of Q BioMed’s Autistic Spectrum Disorder drug development program for non-verbal or minimally verbal autistic children.
SRI has expertise in solving formulation, drug delivery, and characterization challenges of small molecule drugs and biologics.
The formulation team, led by Dr. Gita Shankar, is experienced in the development of novel formulations that have reached clinical trials. They are currently developing a formulation for QBM-001 with relatable chemical properties and formulation requirements.
The preclinical studies for QBM-001 will be led by Dr. Stephen Morairty and his team in SRI’s Center for Neuroscience. Morairty and his colleagues are experienced in working with several preclinical autism models.
“We are pleased to have found both experience with autism models and expertise in formulation of products like QBM-001 in SRI International,” said Denis Corin, CEO of Q BioMed Inc. “This important step will be the catalyst for several milestones for QBM-001 over the next few months as we prepare clinical product for the trials we anticipate starting in 2019.”
QBM-001 targets toddlers with pediatric developmental nonverbal disorder, where an underlying commonality may lead to developmental delay, an autism diagnosis and eventual nonverbal or very minimally verbal capability for the rest of their lives.
(Source: Q BioMed Inc.)
Filed Under: Drug Discovery